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Factors predictive of post-transplant erythrocytosis. Ninety-three pa-
tients with PTE (that is, hematocrit 51% or greater) were identified
among 431 renal transplant recipients, an incidence of 21.6%. Thirty-
eight patients underwent blood volume measurements, and 22 of these
had high red cell volume and therefore were considered to have true
PTE. To analyze factors predictive of erythrocytosis, a control group
with normal hematocrit was randomly selected from our renal trans-
plant population and compared with the 93 patients with PTE, and with
the 22 who had true PTE. Using step-wise logistic regression analysis,
we identified three variables that were consistent predictors of PTE. In
order of significance, the serum creatinine value at the onset of PTE
appears to most strongly predict the occurrence of PTE (P < 0.0001).
As creatinine value increases, the probability of PTE decreases. Next
was immunosuppression, where double immunosuppressive therapy
was associated with a greater probability of PTE than triple therapy (P
<0.0001). The overall incidence of PTE in patients on double therapy
was 34%, while that for those on triple therapy 10.4%. Last was
duration of dialysis for which increasing values correspond to increas-
ing probability of PTE (P = 0.004). Comparison of the serum erythro-
poietin (EPO) levels for patients and controls yielded a nonsignificant
result (P = 0.2507and P = 0.383 for all patients with PTE and true PTE,
respectively), and therefore EPO levels were inappropriately elevated
for the level of hematocrit in the PTE group. Only the number of
rejections and duration of follow-up (r =
—0.3507) were significantly
correlated with EPO (P < 0.05). The incidence of thromboembolic
events was similar in the two groups, and prophylactic phlebotomy did
not reduce the frequency in the PTE patients. The results suggest that
PTE develops in patients in whom the feedback control of EPO
production is impaired against the background of good allograft func-
tion and lower immunosuppressive state.
Erythrocytosis following renal transplantation (PTE) has
been recognized since 1965 [1], and has now been documented
in over 200 cases reported in the English literature [2—81. Two
forms have been described: true erythrocytosis which repre-
sented a state of increased hematocrit and red blood cell volume
(RCV) 171, and spurious or Gaisbock erythrocytosis, whereby
the rise in the hematocrit results from contraction of plasma
volume as in diuretic therapy, hypertension, or excessive loss
of extracellular fluids [5, 8]. Although inappropriate production
of erythropoietin (EPO) has been suspected, the mechanisms
and factors predictive of PTE remain speculative. Previously
suggested etiologic factors include acute and chronic rejections
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[9—14], transplant renal artery stenosis [15, 16], and over
production of EPO by the native kidneys [17]. Less commonly
implicated factors include hydronephrosis [18], hepatic EPO
production [19, 20], androgenic steroids [2], resolution of sec-
ondary hyperparathyroidism [211, and resetting of the threshold
for EPO stimulation. More recently, the dose [3] and type [4] of
immunosuppressive drugs, and the level of allograft function [2]
have been implicated. In these studies, however, critical mea-
surements such as blood volumes and EPO were not done and
no attempt was made to identify factors predictive of PTE.
In the present study, we reviewed our experience with a large
number of patients with PTE and a comparable group of renal
transplant recipients with normal hematocrit in order to define
factors predictive of this entity.
Methods
Post-transplant erythrocytosis developed in 93 of 431 patients
who had retained a functioning renal transplant for at least three
months. Post-transplant erythrocytosis (PTE) was arbitrarily
defined as a hematocrit of 51% or greater observed on two or
more consecutive clinic visits. True PTE was defined as red cell
volume (RCV) greater than 30 ml per kg body weight for
females and greater than 35 ml per kg for males. There were no
patients with pre-transplant erythrocytosis. A group of 93 renal
transplant patients with normal hematocrit was randomly se-
lected from our transplant population to serve as controls.
Patients were studied during their post-transplant follow-up
for possible causes of erythrocytosis. Studies included, but
were not limited to, ultrasonography of the native and trans-
planted kidneys, i hippuran and technetium 99 radioisotope
scanning, pulmonary function studies, arterial blood gas analy-
sis, liver function tests, and parathyroid hormone levels.
Peripheral plasma erythropoietin (EPO) levels were mea-
sured using 125j radioimmunoassay. Plasma volume (PV) was
measured using '251-labeled human serum albumin, and RCV
was determined using chromium-S 1 labeled red blood cells.
We also reviewed all renal transplant clinic records which
show in a tabulated form the type, place and date of transplants,
laboratory data, drugs given, rejection episodes, and treatment
rendered, as well as other relevant information. These records
are started immediately after transplantation and are updated
regularly. Records of patients who undergo transplant abroad
are established when they return to our institution, usually
within two to four weeks after transplantation in living nonre-
lated and two to three months in cadaveric renal transplant
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recipients. In addition, hospital medical records were reviewed
in detail.
Maintenance immunosuppression consisted of either double
therapy (that is, prednisone and azathioprine, or prednisone
and cyclosporine) or triple therapy with prednisone-azathio-
prine-cyclosporine given in standard doses. Rejection episodes
were treated with high-dose steroid or with antilymphocyte
globulin, and since February 1987 with OKT3.
Statistical analyses
An initial descriptive analysis was carried out which included
comparisons of over forty factors between PTE and control
groups. These analyses were for the most part either Wilcoxon
two-sample tests or chi-square tests. Normality checks using
the Kolmogorov-Smirnoff test had shown several of the factors
to be significantly non-Gaussian, and therefore the nonparamet-
nc Wilcoxon test was used.
From among the many comparisons of variables between
patients and controls, several significant ones were detected.
We used step-wise logistic regression analyses to identify which
of the significant variables were truly not significant, but only
appeared so through their association with other significant
factors. This included a phase where various models were
checked (that is, various combinations of main effects and
interactions) until a final model was reached which sufficiently
explained the occurrence of PTE through the items included in
the model and which met the Hosmer-Lemeshow Goodness-
of-fit Test. This study yielded a parsimonious model for pre-
dicting PTE, as well as ranked the significant explanatory
variables according to their apparent importance in explaining
the occurrence of PTE. From among the 186 subjects in this
study, only 111 had complete information for each of the
independent variables in the logistic regression analysis. EPO
was not included in the list of independent variables, because it
was available for too few subjects to adequately carry out a
logistic regression. The step-wise logistic regression analysis
was carried out with the LR program within the 1990 version of
the BMDP/PC statistical software package. The likelihood ratio
criterion was used to test the individual independent variables
with an alpha level for inclusion set at 0.10. A relatively
conservative level of significance was chosen (0.001), to adjust
for the problem of multiple testing within the same dataset.
Results
The clinical and biochemical characteristics of the PTE and
control groups are summarized in Tables 1 to 2. PTE was
identified in 93 of 431 renal transplant recipients whose grafts
had been functioning for more than three months, yielding an
overall incidence of 21.6%. However, the incidence among
living related (LR), cadaveric (CAD), and living non-related
(LNR) renal transplant recipients was 30.0%, 21.5%, and
12.3%, respectively. The difference was statistically significant
when only LR transplants were compared with LNR trans-
plants (P < 0.005). PTE developed in 62 of 182 patients on
double therapy (34.0%) and in only 25 of 240 patients on triple
therapy (10.4%; P < 0.0001). The median onset of PTE was
nine months (range I to 99 months). The median maximum
hematocrit, despite frequent phlebotomies, was 54.6% (range
51.0 to 63.2%). PTE occurred in patients between 13 and 61
years of age (median 34 years). Patients were followed for 1 to
Table 1. Demographic and pretranspiant clinical characteristics of
control, all patients with PTE and patients with True PTE
Control All PTE True PTE
Number 93 93 22
Age, years 33 (12—72) 34 (13._6l)8 34,5 (18—47)
Male/female 62/31 78/15 19/3
Duration of dialysis 11.5 (3—48) 17 (2—72)" 15.5 (4—60)"
months
Hematocrit 24.4 (17.6—38) 24 (l633)C 24 (18—33)
Number of transfusions 6 (0—65) 4 (0—9) 3.5 (0—9)
Number with hypertension 65/93 (70%) 70/93 (75.3%) 16/22 (73%)
Number with abnormal 21/93 (22.6%) 20/93 (21.5%) 4/22 (18%)
liver function tests
Weight kg 52 (24—85) 50 (25—87) 50 (25—75)
Number with 11/93 (11.8%) 7/93 (7.5%) 2/21 (9.5%)
binephrectomy
Number with splenectomy 3/93 (3.2%) 7/93 (7.5%) 2/21 (9.5%)
Values are exposed as median (range: minimum-maximum) where
appropriate.a p < 0.01 All PTE vs. Control
b p < 0.005 All PTE vs. Control and True PTE vs. Control
P 0.08 All PTE vs. Control
Table 2. Posttransplant dinical characteristics
Control All PTE True PTE
Follow-up months 30 (6—150) 49 (l124)a 47 (12—72)
Graft source:
Cadaver 45 42 9
Living related 35 43 12
Living nonrelated 15 8
Onset of PTE months 0 9 (1—99) 5 (1—16)
Duration of PTE months 0 6 (1—60) 11.5 (1—54)
Number of phlebotomies 0 1 (0—11) 2.5 (0—11)
Maximum Hct 43.5 (34—50) 54.6 (51_63.2)8 56.6 (5l_63.2)a
Hypertension 78/93 (84%) 75/93 (80%) 2 1/22 (45%)
Steroid diabetes 26/93 (28%) 18/93 (19.4%) 8/22 (36%)
Diuretics 49/93 (59.7%) 32/93 (344%)b 8/22 (36%)
Number of rejections 1 (0—5) 0 (0—4) 1 (0—2)
Double therapy 20/93 62/938 l6/22a
Triple therapy 70/93 27/938 5/22a
First outpatient 1.2 (0.6—4.0) 1.4 (0.7_2.8)c 1.4 (0.7—2.7)
creatinine
Creatinine at PTE 2.0 (1.0—8.0) 1.4 (O.7_3.1)a 1.4 (0.7_2.4)a
Values are expected as median (range: minimum-maximum) where
appropriate.
a P < 0.00001 All PTE vs. Control and True PTE vs. Controlb p < 0.05 Control vs. All PTE and Control vs. True PTE
P < 0.001 All PTE vs. Control
124 months (median 35 months) after the onset of PTE which
persisted for a median of six months (range 1 to 60 months).
During this period, the median number of phlebotomies was one
(rangeOto 11).
Most patients had symptoms of hyperviscosity such as throb-
bing headache, sense of fullness in the head, dizziness, and
fatigue. Symptoms were relieved by phlebotomy. The decision
to perform phlebotomy was left to the discretion of individual
physicians. In 44 patients who had no phlebotomy, two suffered
myocardial infarction. By contrast, of 49 patients who had
phlebotomy, one suffered myocardial infarction. Thus, only
three patients in the PTE group had thrombotic episodes. On
the other hand, four patients in the control group had throm-
boembolic events, two of these had retinal vein thrombosis, one
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Table 3. Red cell and plasma volumes
PV
RCV
Group A
high
Group B
normal Total
High 1 0 1
Low 8 6 14
Normal 13 10 22
Total 22 16 38
Abbreviations are: RCV, red cell volume; PV, plasma volume.
Table 4. Red cell and plasma volumesa
Group No. BV RCV PV"
A 22 72.8 (50.8—96.7) 38.3 (30—47) 34 (20.3—59.1)
B 16 61.6 (44—75) 30 (25—34) 31 (19—45)
Abbreviations are: BY, blood volume; RCV, red cell volume; PV,
plasma volume.
a Median (range: minimum-maximum)
b pv was lower in patients with posttransplant hypertensions (P =
0.03)
Table 5. Plasma erythropoietin levels
Control All PTE True PTE P value
N 42 36 II
Minimum 10 10 10
Maximum 108 120 45
Mean
Standard deviation
21.88
25.55
25.69
27.21
18.82
11.66
NS
Median 12.0 13.5 11 NS
NS is no significant difference: Control vs. All PTE and Control vs.
True PTE.
had myocardial infarction, and one had cerebrovascular acci-
dent. There was no significant difference in the number of
thromboembolic events between patients with PTE and con-
trols, and between patients who had phlebotomies and those
who did not.
Thirty-eight patients underwent RCV and PV studies (Tables
3 and 4). Twenty-two had an absolute increase in RCV, that is,
true PTE (Group A) and 16 had normal RCV (Group B).
Thirteen of 22 patients in group A had normal PV, eight had
low, and one had increased PV (Table 3). On the other hand, 10
patients in group B had normal PV and six had decreased PV.
There was no difference in the EPO levels between these two
subgroups and diuretics were used more commonly in the
control group (P < 0.05). However, PV was significantly lower
in patients with post-transplant hypertension (P = 0.030). Blood
volumes were not measured in the control group.
The EPO level was obtained in 36 patients, 11 with true PTE,
and 42 controls. Median levels were 13.5 (range: 10 to 120
mU/ml), 11 (range: 10 to 45 mU/mI) and 12 (range: 10 to 108
mU/ml) for all PTE patients, true PTE, and controls, respec-
tively (Table 5). The level of EPO in both the PTE and control
patients varied widely, and there were no statistically signifi-
cant differences between the two groups. Additionally, EPO
level in patients with true PTE did not differ significantly from
that of the control group. In two patients with spurious PTE
(that is, normal RCV and low PV) the EPO level was available
and did not differ from that of patients with true PTE. Finally,
no correlation was found between EPO levels and hematocrit,
total blood volume, red cell volume, allograft source, or serum
creatinine level. Correlation was found, however, between
EPO and the number of rejections (that is, the fewer the
rejection episodes, the higher the serum EPO level). Also,
correlation was found with the duration of follow-up after
transplantation (that is, the shorter the duration of follow-up,
the higher the serum EPO level).
All patients with PTE had ultrasonographic evaluation of the
allograft, and in 49, concomitant examination of the native
kidneys was performed at or near the onset of PTE. Five of 93
patients had minor abnormalities of the allograft, including
small fluid collections around the upper or lower pole in two
patients, small cysts in two, and minor prominence of the
collecting system in one. Of the 49 with native kidney ultra-
sound, four had bilateral nephrectomies, three had one small
cyst in one kidney, one had multiple small cysts in both
kidneys, and one had nephrocalcinosis. By contrast, 69 patients
in the control group had recent ultrasonographic examination of
the allograft and this included the native kidneys in 44. Four
patients showed allograft abnormalities, including one each of
cyst, minor dilatation of the calices, hydronephrosis, and stone.
Four other patients had small fluid collection around the poles
of the allograft. Of the 44 native kidney ultrasounds, six had
bilateral nephrectomies, two had cysts, two had caliceal dilata-
tion, and one had stones.
No patient had a history or clinical manifestation of pulmo-
nary disease and smoking history could not be accurately
obtained. In 46 patients, measurement of arterial blood gases
(ABG) was done at the onset of PTE. Although two patients had
a p02 less than 70 mm Hg, all patients had oxygen saturation in
excess of 90%. In addition, 19 patients had pulmonary function
studies done at the time of ABG determination and these
revealed no significant pulmonary disease.
The median age was similar for the PTE and control groups,
as was other pre-transplant data including transfusions, original
kidney disease, pre-transplant hypertension, number with bilat-
eral nephrectomy, number with abnormal liver function tests,
and weight. However, females were over-represented in the
control group (P < 0.01). Additionally, the control group had
shorter duration of dialysis (median 17 months vs. 11.5 months;
P < 0.005) and higher pre-transplant hematocrit (median 24%
vs. 24.4%; P = 0.08; Table 1). On the other hand, post-
transplant data showed differences in the duration of follow-up
after transplantation (median 49 months, range 13 to 134) versus
30 months (range 6 to 150), respectively, for patients and
controls (P < 0.005), in the immunosuppressive drugs used, and
in the allograft function (Table 2). In the PTE group, 72% were
either on prednisone-azathioprine or prednisone-cyclosporine
(double therapy), while only 25% of the control group were
receiving such therapy (P < 0,0001). When comparisons were
made for patients with true PTE, the same results were ob-
tained.
PTE occurred in patients with good allograft function (Table
2). The median first outpatient serum creatinine level after
transplantation was 1.4 mgldl (range 0.7 to 2.8) and that of
controls was 1.2 mg/dl (range 0.6 to 4.0; P < 0.001). By
contrast, the serum creatinine level at the time of diagnosis of
PTE was 1.4 mg/dl (range 0.7 to 3.1), and that of the control
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group before their highest hematocrit was 2.0 mgldl (range 1.0
to 7.0; P < 0.0001). Furthermore, in 82 patients the serum
creatinine level was less than 2.0 mg/dl at the onset of PTE.
However, the median serum creatinine value at the last fol-
low-up was 1.5 mgldl for the PTE patients (range 0.7 to 9.9)
which was not significantly different from the 1.6 mg/dl for the
controls (range 0.9 to 9.0), and was also similar for CAD, LNR,
and LR transplant recipients. The number of patients and
controls who had a rejection episode was similar and the
number of rejections in both groups was also similar. Overall,
96.8% of patients and 97.4% of controls were alive at the end of
the follow-up period.
Renal artery stenosis was not specifically looked for in either
group, but the prevalence of hypertension was similar. Obstruc-
tive uropathy was observed in one patient with PTE and in none
of the controls. Abnormal liver function test results were
similar in both groups. Similarly, there was no difference
between the two groups in the frequency of each HLA antigen.
As can be recognized, comparisons between patients and
controls revealed several variables that differ significantly.
Subsequently, both univariate and multivariate logistic regres-
sion analysis was carried out (Figs. 1 to 4). The serum creati-
nine level at the onset of PTE for all patients and for those with
true PTE appeared to most reliably predict the occurrence of
PTE (P < 0.0001). Its estimated coefficient was negative,
indicating that for increasing values of creatinine the probability
of PTE decreases (Figs. 1 and 2). Next in order of significance
was the type of immunosuppressive regimen used, with patients
receiving double immunosuppression therapy there was a sig-
nificantly higher probability of developing PTE than in those
receiving triple therapy (P <0.0001; Figs. 2 and 3). In addition,
the probability of PTE was higher with increasing duration of
dialysis (Fig. 4), but this was not as strong a predictor of PTE as
the first two factors, particularly in multivariate analysis (P =
0.004). The initial serum creatinine level was also a predictive
factor, but its coefficient was positive, indicating that for
increasing creatinine values the probability of PTE increases.
However, when the analysis was done for patients with true
Creatinine (mg/dI) at PTE
Fig. 2. Multivariate logistic regression of serum creatinine (mg/dl) at
PTE, and immunosuppressive therapy using all patients with PTE.
Symbols are (—) double therapy; ( ) triple therapy. The estimated
coefficients were —18.21 and —12.14 for creatinine at PTE and immu-
nosuppression type, respectively, indicating an estimated decrease in
the probability of PTE with increasing creatinine levels (P < 0.0001),
and a higher probability of PTE for patients on double immunosuppres-
sive therapy (P < 0.0001).
Creatinine (mg/dI) at PTE
Fig. 3. Multivariate logistic regression of serum creatinine (mg/dl) at
PTE, and type of immunosuppression; (—) for double; ( ) for triple
therapy; using 22 patients with true PTE. The estimated coefficients
were —4.202 and —3.873 for creatinine at PTE and type of immurlosup-
pression, respectively. This indicates that there is an estimated de-
crease in the probability of PTE with increasing creatinine levels (P <
0.0001), and higher probability of PTE in patients on double immuno-
suppressive therapy (P < 0.0001).
PTE this item was not a significant predictive factor. The reason
for that is not clear, but could be related to the fact that the
initial outpatient serum creatinine for patients transplanted
abroad, particularly in the USA, was not truly the initial
outpatient creatinine since these patients returned to us two to
six months post-transplantation.
Discussion
The pathogenesis of PTE is unclear. Previous studies have
shown that EPO production is enhanced several-fold by the
functioning allograft within two to four weeks from the onset of
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FIg. 1. Univariate logistic regressions of creatinine (mg/dl) at PTE
using all patients with PiE (—), and using those patients with true PTE
). The estimated coefficients were —1.966 and —2.978, respec-
tively, indicating an estimated decrease in the probability of PTE with
increasing serum creatinine levels (P < 0.0001).
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Fig. 4. Univariate logistic regressions of duration of dialysis using 85
patients with PTE (—), and using 22 patients with true PTE ( ). The
estimated coefficients were 0.0414 and 0.0433, respectively, indicating
an estimated increase in the probability of PTE with increasing duration
of dialysis (P = 0.004).
diuresis, followed by a slow return to normal as the hematocrit
rises above 32% [22, 23]. This usually results in correction of
anemia within 6 to 12 weeks in a manner reminiscent to that
which occurs in dialysis patients who receive recombinant
human erythropoietin [23]. However, patients with erythrocy-
tosis have persistently elevated serum EPO levels [22, 23].
Because differentiation and maturation of red blood cells are
under the control of EPO, raised EPO levels are implicated in
PTE [241. Webb et al proposed that restoration of an almost
normal milieu interieur by a fully functioning kidney results in
excess erythropoiesis [3]. In most patients, this is normally held
in check by the immunosuppressive agents, but in patients who
are destined to develop PTE, erythropoiesis becomes unre-
strained, leading to erythrocytosis. Alternatively, other causes
of erythrocytosis after transplantation have been proposed.
Dagher et al [17] and Thevenod et al [24] indicated that the
transplanted kidney worked within the normal range of feed-
back regulation, but that erythrocytosis resulted from an in-
creased disordered release of EPO from the native kidneys. In
some patients, escape from the normal feedback regulation may
result from either autonomous EPO production or from feed-
back regulation at a higher hematocrit level [24].
In our series, it was interesting to find normal but comparable
EPO levels in PTE patients and controls as well as in patients
with true PTE, that is, inappropriately elevated for the degree
of erythrocytosis. EPO levels were higher in patients with fewer
rejection episodes and with shorter post-transplant follow-up
period. These levels, however, were obtained at the onset of
PTE and therefore may not reflect levels prevailing during the
early post-transplant period. Unfortunately, serial EPO levels
and ferrokinetic studies were not done in our patients. This
could have shed some light on both the pathogenesis of PTE as
well as its transient nature. EPO levels are usually low and high
in primary and secondary polycythemia, respectively [251, and
therefore one would expect patients with PTE to have EPO
levels much lower than those of the controls unless the eryth-
rocytosis in these patients is secondary to factors known to
stimulate EPO production. Also, PTE in these patients is
transient in nature. This may be related to decreasing EPO
levels with time [23], and to decreased ferritin levels to below
normal which were reported to contribute to stabilization of the
hematocrit in patients with PTE [23]. This tertiary form of
erythrocytosis may be unique to renal transplant patients as it
falls somewhere between the primary and secondary forms of
erythrocytosis.
The present study has attempted to define factors predictive
of PTE. To our knowledge, this approach has not been previ-
ously reported in the literature. Three factors were found to
consistently predict the occurrence of PTE. These are: 1) the
serum creatinine level at the onset of PTE; 2) the type of
immunosuppression used; and 3) the duration of dialysis. De-
layed allograft function delays erythropoiesis, and the degree of
correction of anemia is ultimately limited by the level of
allograft function attained, as estimated by serum creatinine
levels [22]. In our patients, the median serum creatinine level at
the onset of PTE was significantly lower than that achieved in
the control group, implying that continued good allograft func-
tion may be pivotal in the erythrocytosis process. This also
suggests that the allograft is the main source of EPO, although
the role of the native kidneys cannot be excluded [2, 17].
Azathioprine is a recognized myelosuppressant but is not
detrimental to allograft function. On the other hand, cyclospo-
rine has no myelosuppressive properties, but in fact may
contribute to the development of PTE through the employment
of various mechanisms, including: (1) direct and indirect stim-
ulation of bone marrow precursors possibly by inhibiting the
killer cell function and lymphokine production which may
directly suppress primitive red cell precursors [3, 26], or [2] it
may augment production of EPO via afferent arteriolar constric-
tion which results in renal cortical hypoxia, or through inhibi-
tion of renal prostaglandin synthesis [22]. However, cyclospo-
rifle has powerful nephrotoxic effects and therefore, given
together, the combined myelosuppressive effects of azathio-
prine and the nephrotoxic effects of cyclosporine may render
renal transplant patients more resistant to the development of
PTE as compared with patients on either drug alone. In
addition, cortisone treatment could lead to an intensified pro-
liferative capacity or increase of erythroid stem cells [27].
Several studies have described an influence of immunosup-
pressive drugs on the frequency of PTE. In a group of patients
treated with azathioprine and prednisone, Webb et al [3] found
that patients with PTE had received a significantly lower dose
of azathioprine compared with a control group. The mean
azathioprine dosage taken over a six-month period prior to the
highest recorded hemoglobin level correlated inversely with the
development of PTE and the total white cell count. They
suggested that marrow activity is restrained by a direct effect of
azathioprine on the bone marrow, and the increased incidence
of PTE may be a consequence of reduced azathioprine dosage.
Nonetheless, in a similar study, Teruel et al found no difference
in the azathioprine dosage between patients and controls [28].
On the other hand, Webb et al [3] speculated that the increasing
use of cyclosporine may be associated with an increasing
frequency of PTE. This view was supported by Gruber et al [4]
who found a higher, but nonsignificant incidence of PTE in their
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
w
I—0
0
.0
.000
1158 Qunibi et a!: Post-transplant erythrocytosis
cyclosporine-treated patients when compared with azathio-
prine-treated patients (9.4% vs. 3.7%, P 0.08). However, we
[28, 291 could not substantiate these observations. On the other
hand, the longer duration of dialysis and the lower pre-trans-
plant hernatocrit may have increased the sensitivity of the
hematopoietic progenitor cell response to EPO [311. However,
this was not a strong predictor of PTE as the first two factors.
A genetic predisposition to PTE has been suggested recently.
Stockenhuber et al [30] reported an association between
HLA-A2 gene frequency and PTE. Similarly, Sun et al [231
reported an association with HLA-C3. In our series, represent-
ing a much larger number of patients, no such association was
found.
PTE is now regarded as a frequent complication among renal
transplant recipients. The reported incidence varies between
3.8% and 25% [2, 5, 8, 10, 19, 28, 29]. The overall incidence in
our study was 21.6%, and this generally concurs with those
reported elsewhere. Nevertheless, PTE is a self-limited process
and its transient nature is well established [2—41. Intermittent
phtebotomies were performed to maintain the hematocrit under
51%, but the decision to employ this measure was left to
individual physicians caring for these patients. Patients experi-
enced alleviation of symptoms and did not have any undesirable
consequences from phlebotomy. Thrombotic episodes have
been reported in patients with both true and spurious erythro-
cytosis [31]. Pollak et al reported no thromboembolic events in
their patients with PTE in whom cessation of diuretic therapy
was followed by a decline in hematocrit to less than 50% [5]. In
another study, 10% of patients with PTE had at least one
episode of phlebitis, and another 10% suffered cerebrovascular
accidents [2]. However, 28% of their patients with PTE were
diabetic, with their inherent susceptibility to peripheral, cardio-
vascular, as well as cerebrovascular diseases. Obermiller et at
reported five patients with PTE, but only one suffered a
thrombotic cerebrovascular accident at 36 months post-trans-
plant when his hematocrit was 60% [8]. Gruber et al [4] found
no significant differences in the frequency of thromboembolic
events among subgroups of phlebotomized or nonphleboto-
mized patients with PTE. Therefore, our experience in 44
patients with PTE who underwent no prophylactic phlebotomy
suggests that phlebotomy may be required only in patients with
signs and symptoms of hyperviscosity and in the context of
other co-morbid states such as cardiovascular or cerebral
disease and in patients with a history of thromboembolic
events. This has also been the recommendation of others [5].
Theophylline, an adenosine antagonist, was recently shown to
eliminate the need for phlebotomy in PTE patients by decreas-
ing EPO levels and normalizing the hematocrit [32]. It may
accordingly be useful in symptomatic patients with true eryth-
rocytosis and high serum EPO levels. There is little justification
for phlebotomy in patients with Gaisbock erythrocytosis [5, 6].
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